Clinical Trials in ROP
Retinopathy of prematurity (ROP) affects the developing retina, with approximately 28,300 to 45,600 infants diagnosed globally each year. [Stahl.Lancet.2019] Low birth weight and low gestational age are major risk factors for ROP. [Mirghorbani M.Int J Vitreous Retina.2022] Although mild ROP may resolve on its own, severe ROP can lead to retinal detachment, vision impairment, and blindness. [Stahl.Lancet.2019] Treatments for ROP include lasers, anti-vascular endothelial growth factor (VEGF) injections, and ocular surgery. Laser treatment has been around longer than anti-VEGF injections, but longer-term risks with laser therapy include visual field loss and high myopia. Concerns with anti-VEGF injections include potential systemic exposure to anti-VEGF agents and a higher risk of recurrent ROP compared with laser treatment. [Mirghorbani M.Int J Vitreous Retina.2022]
This section lists the most relevant clinical trials/studies for ROP. Click on the study name to see more details about each particular study. To enhance visibility of graphs and tables, click on the image to enlarge for expanding viewing.